SCHEMBL19717877

SCHEMBL19717877

O=C(O)N1CC(O)(c2ccc(OCc3c(-c4c(Cl)cc(F)cc4Cl)noc3C3CC3)cc2Cl)C1

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 20/20 0.75
HSD17B13 Q7Z5P4 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29735903 0.89 NR1H4 (0.68) NR1H4HSD17B13
SCHEMBL19689504 0.89 NR1H4 (0.68) NR1H4HSD17B13
SCHEMBL19725194 0.89 NR1H4 (0.73) NR1H4HSD17B13
SCHEMBL19698943 0.87 NR1H4 (0.69) NR1H4HSD17B13
SCHEMBL31175985 0.86 NR1H4 (0.87) NR1H4HSD17B13
SCHEMBL22233106 0.86 NR1H4 (0.87) NR1H4HSD17B13
SCHEMBL29760423 0.86 NR1H4 (1.00) NR1H4HSD17B13
SCHEMBL31175986 0.86 NR1H4 (0.87) NR1H4HSD17B13
SCHEMBL19689514 0.86 NR1H4 (1.00) NR1H4HSD17B13
SCHEMBL30775167 0.86 NR1H4 (0.68) NR1H4HSD17B13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2022-06-30 US disclosed
US-20220204491-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-06-30 US disclosed
US-11225473-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2022-01-18 US disclosed
EP-3911647-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-11-24 EP disclosed
US-20200255418-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2020-08-13 US disclosed
WO-2020150136-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2020-07-23 WO disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225473-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 NR1H4 1/4885HSD17B13 707/4885
US-20220204491-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 NR1H4 1/4885HSD17B13 707/4885
US-20200255418-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 NR1H4 1/4885HSD17B13 707/4885
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 NR1H4 1/4885HSD17B13 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.